home / stock / immpf / immpf news
(NewsDirect) ImmuPharma PLC (AIM:IMM) chief executive Tim McCarthy provides an extensive update during an interview with Proactive's Stephen Gunnion, focusing on the financial, business, and portfolio developments of the company. McCarthy clarified that the company is in a strong fina...
(NewsDirect) ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that the specialty biopharmaceutical will be moving forward into a key phase 2/3 adaptive clinical trial, alongside its US part...
(NewsDirect) Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com Copyright (c) 2023 TheNewswire - All rights reserved.
(NewsDirect) ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio, following what he calls a "very busy time" for the specialty biopharmaceutical company. He discusses the latest developments and next steps for the P140 platf...
(NewsDirect) ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio after announcing that its partner Avion Pharmaceuticals is to launch an adaptive phase II/III clinical study on Lupuzor, the former’s discovery and putative...
News, Short Squeeze, Breakout and More Instantly...
Immupharma PLC Company Name:
IMMPF Stock Symbol:
OTCMKTS Market:
(NewsDirect) ImmuPharma PLC (AIM:IMM) chief executive Tim McCarthy provides an extensive update during an interview with Proactive's Stephen Gunnion, focusing on the financial, business, and portfolio developments of the company. McCarthy clarified that the company is in a strong fina...
(NewsDirect) ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that the specialty biopharmaceutical will be moving forward into a key phase 2/3 adaptive clinical trial, alongside its US part...
(NewsDirect) Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com Copyright (c) 2023 TheNewswire - All rights reserved.